Comprehensive Bioinformatic Characterization of CD70, CD80, and TIGIT as Diagnostic, Prognostic, and Immune Biomarkers in Pan-Cancer
Christos Panagiotis Rigopoulos, Ilias Georgakopoulos-Soares, Apostolos Zaravinos · 2026
Read Comprehensive Bioinformatic Characterization of CD70, CD80, and TIGIT as Diagnostic, Prognostic, and Immune Biomarkers in Pan-Cancer by Christos Panagiotis Rigopoulos, Ilias Georgakopoulos-Soares, Apostolos Zaravinos (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13297921.txt.
Description
Three immune molecules may help read a tumor's prognosis and likely drug response across many cancers, propose Christos Panagiotis Rigopoulos and co-authors in a 2026 data study. They profiled CD70, CD80, and TIGIT through cancer genome data spanning gene expression, methylation, mutations, and single-cell records.
All three molecules were widely misregulated, with joint overexpression standing out in clear-cell kidney cancer. Higher levels tracked with advanced stage and worse survival in selected cancers, including uveal melanoma and kidney tumors. Expression also lined up with immune cell mixes, TIGIT marking T-cell-inflamed tumors, and with sensitivity to several anticancer drugs in cell lines. The authors present the trio as candidate biomarkers for precision immunotherapy.
Catalog record
| CREATOR | Christos Panagiotis Rigopoulos, Ilias Georgakopoulos-Soares, Apostolos Zaravinos |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 45595 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |